OVATF (Ovation Science) EBIT: $-0.42 Mil (TTM As of Mar. 2026)


What is Ovation Science EBIT?

Ovation Science OVATF EBIT is $-0.42 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Ovation Science's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-0.07 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.42 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ovation Science's annualized ROC % for the quarter that ended in Mar. 2026 was -137.20%. Ovation Science's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ovation Science's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -72.34%.

Ovation Science  (OTCPK:OVATF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ovation Science's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-0.284 * ( 1 - 0% )/( (0.205 + 0.209)/ 2 )
=-0.284/0.207
=-137.20 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.06 - 0.913 - ( 0.052 - max(0, 1.118 - 0.06+0.052))
=0.205

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.036 - 0.985 - ( 0.028 - max(0, 1.194 - 0.036+0.028))
=0.209

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Ovation Science's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.284/( ( (0 + max(-0.909, 0)) + (0 + max(-0.981, 0)) )/ 2 )
=-0.284/( ( 0 + 0 )/ 2 )
=-0.284/0
= %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.004 + 0 + 0) - (0.913 + 0 + 0)
=-0.909

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.005 + 0 + -0.001) - (0.985 + 0 + 0)
=-0.981

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ovation Science's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-0.421/0.582
=-72.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ovation Science EBIT Related Terms

Ovation Science EBIT Historical Data

* Premium members only.

The historical data trend for Ovation Science's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ovation Science EBIT Chart

Ovation Science Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only -1.87 -0.58 -0.58 -0.29 -0.42

Ovation Science Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.09 -0.09 -0.17 -0.07

OVATF vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ovation Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ovation Science EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ovation Science's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ovation Science's EV-to-EBIT falls into.


Ovation Science EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-0.42 Mil mean?
Ovation Science (OVATF) has a EBIT of $-0.42 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ovation Science.
Is Ovation Science's EBIT too high?
Ovation Science's current EBIT is $-0.42 Mil.
How does Ovation Science's EBIT compare to ZTS?
Ovation Science's EBIT of $-0.42 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ovation Science. Ovation Science's current EBIT is $-0.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovation Science stock overvalued right now?
Based on GuruFocus' analysis, Ovation Science (OVATF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $0.04 — trading 16.7% above its estimated fair value. The current EBIT is $-0.42 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Ovation Science (OVATF), the current EBIT is $-0.42 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ovation Science Business Description

Other Exchanges OVAT:Canada
Address 1166 Alberni Street, Suite 1003, Vancouver, BC, CAN, V6E 3Z3
Ovation Science Inc. is a Canada-based company mainly engaged in the business of providing topical and transdermal cannabis products under the Ovation brand label, utilizing patented Invisicare delivery technology. The Company operates in one reportable operating segment, the sub-licensing and sales of cannabis products that utilize Invisicare, a patented polymer-based technology for topical and transdermal skin care products.